A New Standard

When it comes to cancer,
“maybe” is not an answer

MammaPrint: a test to predict risk of breast cancer recurrence

The clarity that MammaPrint delivers helps patients and physicians make informed, confident treatment management decisions.

MammaPrint is FDA-cleared for women of all ages. MammaPrint is also available via next generation sequencing on the Illumina MiSeq platform as an LDT.

The test is validated by peer-reviewed data and supported by the highest level of clinical evidence from a landmark randomized,* prospective, phase IIIclinical trial known as MINDACT.

Impacted by COVID-19? You may be eligible for a deferred payment plan.
[email protected]

Over 75,000 women have chosen MammaPrint to help provide greater clarity on their risk of breast cancer recurrence. Find out more about MammaPrint and recent developments in breast cancer research.

MammaPrint test report

MammaPrint provides a clear low risk or high risk result to better predict breast cancer recurrence

MammaPrint High Risk

MammaPrint Low Risk

-1.000MammaPrint index (MPI)+1.000

A high risk result means that a patient has a statistically significant (11.7%) chance that her cancer will recur within 5 years
1
View high risk report

A low risk result means that a patient has a statistically significant (1.3%) chance that her cancer will recur within 5 years
1
View low risk report

46%
46%

Of physicians had complete or high confidence in their treatment recommendations after receiving the MammaPrint test result2.

Recommended by expert medical guidelines

MammaPrint is included in numerous clinical practice guidelines developed by world-recognized cancer care organizations. Clinical guidelines are evidence-based recommendations for healthcare professionals involved in the management of patients.

Guidelines aim to improve the quality of care and services based on the most up to date peer-reviewed evidence. For example, MammaPrint is the only test of its kind endorsed by the American Society of Clinical Oncology for lymph node-positive patients.

Also included in the National Comprehensive Cancer Network® (NCCN®).
70-Gene Assay (MammaPrint) has a Category 1 recommendation from the National Comprehensive Cancer Network® (NCCN®). Category 1 is based upon high-level evidence; there is uniform NCCN consensus that intervention is appropriate. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2019. © 2019 National Comprehensive Cancer Network, Inc 2019. All rights reserved. To view the most recent and complete version of the guidelines, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

70-gene Assay (MammaPrint) is the only genomic assay with FDA clearance and Level 1 evidence by the American Society of Clinical Oncology (ASCO).

Where to next?

Published Studies
Contact Us
Ordering Portal
BluePrint

I kept thinking maybe I’d made the wrong decision, maybe I should have had a mastectomy. MammaPrint allowed me to calm down, refer back to my results, and return to the faith I had in my treatment.— Mary, a breast cancer survivor

*Randomization is a procedure to allocate clinical study participants into different groups. By using chance to allocate participants, the groups are likely to be similar and allow the effects of the treatments to be compared more fairly.When patients are recruited to a clinical study and followed forward in time.A type of clinical trial designed to confirm and expand on the safety and/or effectiveness of an intervention from earlier clinical trials. Phase III trials are often large and may consist of hundreds or even thousands of patients.REFERENCE1Drukker, C.A., et al. Int J Cancer. January 2013; 133: 929–936 (RASTER)2Wuerstlein R, et al. Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIMe Decision Impact Study. Poster presented at San Antonio Breast Cancer Symposium. December 2016; San Antonio, Texas